Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended March 2023, Integra LifeSciences (IART) reported revenue of $380.85 million, up 1.1% over the same period last year. EPS came in at $0.74, compared to $0.74 in the year-ago quarter.
The reported revenue represents a surprise of +2.00% over the Zacks Consensus Estimate of $373.38 million. With the consensus EPS estimate being $0.74, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Revenue Growth: 4.6% versus the five-analyst average estimate of 2.49%.
Revenue- Codman Specialty Surgical- Total: $248.14 million versus the seven-analyst average estimate of $246.73 million. The reported number represents a year-over-year change of +0.3%.
Revenue- Tissue Technologies- Total: $132.71 million versus $126.66 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +2.6% change.
Revenue- Codman Specialty Surgical- Instruments: $55.27 million versus the five-analyst average estimate of $53.19 million. The reported number represents a year-over-year change of +5%.
Revenue- Tissue Technologies- Private Label: $31.77 million compared to the $32.25 million average estimate based on five analysts. The reported number represents a change of -8.4% year over year.
Revenue- Codman Specialty Surgical- Neurosurgery: $192.87 million versus $195.34 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.
Revenue- Tissue Technologies- Wound Reconstruction and Care: $100.94 million versus the four-analyst average estimate of $94.61 million. The reported number represents a year-over-year change of +6.7%.
View all Key Company Metrics for Integra here>>>
Shares of Integra have returned +6.1% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report
